V
Veli-Matti Kähäri
Researcher at Turku University Hospital
Publications - 228
Citations - 18368
Veli-Matti Kähäri is an academic researcher from Turku University Hospital. The author has contributed to research in topics: Matrix metalloproteinase & Extracellular matrix. The author has an hindex of 68, co-authored 214 publications receiving 17328 citations. Previous affiliations of Veli-Matti Kähäri include University of Helsinki & Thomas Jefferson University.
Papers
More filters
Journal ArticleDOI
Regulation of matrix metalloproteinase expression in tumor invasion
TL;DR: The role of mitogen‐activated protein kinases and AP‐1 and ETS transcription factors in the regulation of MMP gene expression during invasion process is focused on.
Journal ArticleDOI
Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets.
Pia Vihinen,Veli-Matti Kähäri +1 more
TL;DR: The current view on the feasibility of MMPs as prognostic markers and as targets for therapeutic intervention in cancer is discussed.
Journal ArticleDOI
Matrix metalloproteinases in skin
TL;DR: The role of MMPs and TIMPs in human skin based on new observations on the regulation of the expression of M MPs, on their substrate specificily, and MMP expression in physiologic and pathologic conditions of skin involving matrix remodeling are discussed.
Journal ArticleDOI
CIP2A Inhibits PP2A in Human Malignancies
Melissa R. Junttila,Pietri Puustinen,Minna Niemelä,Minna Niemelä,Raija Ahola,Hugh Arnold,Trine Bøttzauw,Risto Ala-aho,Christina Nielsen,Johanna Ivaska,Johanna Ivaska,Yoichi Taya,Shi-Long Lu,Shujun Lin,Edward K. L. Chan,Xiao-Jing Wang,Reidar Grénman,Reidar Grénman,Juergen Kast,Tuula Kallunki,Rosalie C. Sears,Veli-Matti Kähäri,Veli-Matti Kähäri,Jukka Westermarck,Jukka Westermarck,Jukka Westermarck +25 more
TL;DR: The data show that CIP2A is a human oncoprotein that inhibits PP2A and stabilizes c-Myc in human malignancies and promotes anchorage-independent cell growth and in vivo tumor formation.
Journal ArticleDOI
Role of thymic peptides as transmitters between the neuroendocrine and immune systems.
TL;DR: The role of MMPs and their inhibitors in tumour invasion as a basis for prognostic purposes and for targeted therapeutic intervention in cancer is discussed.